Dr. Tina Bhutani reviews real-world data showing improved patient-reported outcomes and satisfaction with tildrakizumab in moderate-to-severe plaque psoriasis.
Topics Covered:
- Tildrakizumab 100mg over 64 weeks
- Patient-reported outcomes in plaque psoriasis
- Real-world treatment satisfaction and symptom relief
- Insights from the October 2024 JCAD publication